CTOs on the Move

MAP Pharmaceuticals

www.mappharma.com

 
MAP Pharmaceuticals is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mappharma.com
  • 2400 Bayshore Pkwy Suite 200
    Mountain View, CA USA 94043
  • Phone: 650.386.3100

Executives

Name Title Contact Details

Similar Companies

BOCA PHARMACAL INC

BOCA PHARMACAL INC is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Deciphera

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.

Haichang

Zhejiang Haichang is a biopharmaceutical company based in Hangzhou, China. They specialize in the development of mRNA vaccines, nucleic acid drug delivery, and lipid nanoparticle technologies.

AZPerio

AZPerio is home to the state’s leading board-certified periodontists, expertly guided by a patient-first philosophy and collaborative approach. With eight locations throughout Arizona, we are committed to client service, clinical excellence and providi...

Metabolic Solutions Development

Metabolic Solutions Development Company, LLC (MSDC) discovers and develops novel molecular targets and new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially insulin resistance and type 2 diabetes. The company has raised nearly $55 million in support of the development of its novel therapeutic drugs, MSDC-0160 and MSDC-0602, which selectively modulate mitochondrial control of to important cellular activities, such as carbohydrate, lipid, and amino acid metabolism, that are out of balance in patients with type 2 diabetes. Such imbalances may also play a role in other diseases of aging such as Alzheimer’s disease and Parkinson’s disease, as well certain genetic diseases such as polycystic kidney disease.